Brendan Smith
Stock Analyst at TD Cowen
(4.85)
# 389
Out of 4,974 analysts
286
Total ratings
57.4%
Success rate
30.4%
Average return
Main Sectors:
Stocks Rated by Brendan Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OABI OmniAb | Reiterated: Buy | $3 → $5 | $4.35 | +14.94% | 12 | Aug 17, 2026 | |
| MXCT MaxCyte | Reiterated: Buy | n/a | $1.19 | - | 12 | Aug 13, 2026 | |
| ABSI Absci | Reiterated: Buy | n/a | $7.94 | - | 10 | Aug 11, 2026 | |
| CDXS Codexis | Reiterated: Hold | $2 | $1.40 | +42.86% | 11 | Aug 11, 2026 | |
| MASS 908 Devices | Reiterated: Buy | n/a | $9.97 | - | 11 | Aug 11, 2026 | |
| PASG Passage Bio | Reiterated: Hold | n/a | $4.77 | - | 11 | Aug 10, 2026 | |
| BLFS BioLife Solutions | Reiterated: Hold | $31 | $36.39 | -14.81% | 13 | Aug 7, 2026 | |
| DNA Ginkgo Bioworks Holdings | Downgraded: Hold | $12 → $9 | $6.99 | +28.76% | 14 | Aug 7, 2026 | |
| HALO Halozyme Therapeutics | Rated: Buy | $96 → $105 | $106.25 | -1.18% | 24 | Aug 7, 2026 | |
| ABCL AbCellera Biologics | Reiterated: Buy | n/a | $11.41 | - | 11 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $33 | $33.03 | -0.09% | 12 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $4.89 | +2.25% | 12 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.24 | - | 11 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $23.25 | -13.98% | 12 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $6.90 | +1.45% | 12 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $8.40 | +7.14% | 10 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $89 → $115 | $138.10 | -16.73% | 18 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 | $174.73 | +14.46% | 11 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $410 | $365.00 | +12.33% | 7 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $4 → $2 | $1.63 | +22.70% | 10 | Jul 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $2 | $28.03 | -92.86% | 1 | Jul 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $16 | $18.41 | -13.09% | 5 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.15 | - | 7 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $70.67 | n/a | 12 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $20.38 | n/a | 11 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $14 → $9 | $9.23 | n/a | 6 | Nov 12, 2024 |
OmniAb
Aug 17, 2026
Reiterated: Buy
Price Target: $3 → $5
Current: $4.35
Upside: +14.94%
MaxCyte
Aug 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.19
Upside: -
Absci
Aug 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $7.94
Upside: -
Codexis
Aug 11, 2026
Reiterated: Hold
Price Target: $2
Current: $1.40
Upside: +42.86%
908 Devices
Aug 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.97
Upside: -
Passage Bio
Aug 10, 2026
Reiterated: Hold
Price Target: n/a
Current: $4.77
Upside: -
BioLife Solutions
Aug 7, 2026
Reiterated: Hold
Price Target: $31
Current: $36.39
Upside: -14.81%
Ginkgo Bioworks Holdings
Aug 7, 2026
Downgraded: Hold
Price Target: $12 → $9
Current: $6.99
Upside: +28.76%
Halozyme Therapeutics
Aug 7, 2026
Rated: Buy
Price Target: $96 → $105
Current: $106.25
Upside: -1.18%
AbCellera Biologics
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.41
Upside: -
Aug 5, 2026
Reiterated: Hold
Price Target: $20 → $33
Current: $33.03
Upside: -0.09%
Aug 5, 2026
Reiterated: Hold
Price Target: $5
Current: $4.89
Upside: +2.25%
Aug 5, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.24
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: $20
Current: $23.25
Upside: -13.98%
Aug 5, 2026
Reiterated: Buy
Price Target: $7
Current: $6.90
Upside: +1.45%
Aug 4, 2026
Reiterated: Buy
Price Target: $9
Current: $8.40
Upside: +7.14%
Aug 3, 2026
Rated: Buy
Price Target: $89 → $115
Current: $138.10
Upside: -16.73%
Jul 28, 2026
Reiterated: Buy
Price Target: $200
Current: $174.73
Upside: +14.46%
Jul 23, 2026
Rated: Buy
Price Target: $410
Current: $365.00
Upside: +12.33%
Jul 15, 2026
Downgraded: Hold
Price Target: $4 → $2
Current: $1.63
Upside: +22.70%
Jul 14, 2026
Downgraded: Hold
Price Target: $2
Current: $28.03
Upside: -92.86%
Jul 9, 2026
Reiterated: Hold
Price Target: $16
Current: $18.41
Upside: -13.09%
May 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.15
Upside: -
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $70.67
Upside: n/a
May 6, 2025
Reiterated: Buy
Price Target: n/a
Current: $20.38
Upside: n/a
Nov 12, 2024
Reiterated: Hold
Price Target: $14 → $9
Current: $9.23
Upside: n/a